Search Results 101-110 of 17597 for colitis

  1. Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  2. Scott Hennen on Ulcerative Colitis and Mayo Clinic

    ... colitis, which was first diagnosed in 1997. Scott had previously described his reasons for being public about his medical condition in this post. In the ...

  3. A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) - Mayo Clinic

    A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) · Overview.

  4. A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis - Mayo Clinic

    ... Colitis. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information. Overview. Tab Title ...

  5. A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors - Mayo Clinic

    ... colitis (UC) who are refractory to or intolerant of TNF inhibitors. Participation eligibility. Participant eligibility includes age, gender, type and stage ...

  6. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) - Mayo Clinic

    - Diagnosis of Crohn's disease or indeterminate colitis - Suspicion of ischemic, radiation, microscopic, or infectious colitis - Prior colectomy - Prior ...

  7. Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis - Mayo Clinic

    ... colitis (UC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns ...

  8. AMG 181 Phase 2 Study in Subjects with Moderate to Severe Ulcerative Colitis - Mayo Clinic

    AMG 181 Phase 2 Study in Subjects with Moderate to Severe Ulcerative Colitis. Print details. Share; Facebook · Twitter. Overview; Participation eligibility ...

  9. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis · More about research at Mayo Clinic.

  10. Inflammatory bowel disease (IBD) - Doctors and departments - Mayo Clinic

    ... colitis. Mayo Clinic researchers conducted the first clinical study of mesalamine and discovered that genetic differences significantly affected the way ...